Abstract Details

Title Longitudinal Remote Monitoring of Physical Activity and Falls in Progressive Supranuclear Palsy

Topic Movement Disorders

Presentation(s) P3 - Poster Session 3 (11:45 AM-12:45 PM)

Poster/Presentation
Number 5-030

Objective To validate the use of wearable sensors in monitoring physical activity and function in progressive supranuclear palsy (PSP).

Background Digital health technologies can offer objective and measurable insights into diseases right from participants' homes. While wearable sensors have been successfully used to monitor Parkinson's disease activity, there have been few studies in individuals with PSP.

Design/Methods To date the study has recruited 24 individuals with PSP who are being followed for up to 12 months. Every three months, participants complete the PSP Rating Scale. Participants are given a PAMSys™ pendant sensor (BioSensics LLC, Newton MA, USA) to wear for 7 consecutive days every 3 months. The PAMSys sensors measure over 40 different physical activity parameters, including various walking metrics and falls tracked over time. We employed repeated measures correlations to assess the longitudinal correlation between clinical scores and sensor-derived measures.

Results The interim analysis of data collected from the first 15 subjects shows a compliance of 100% in wearing the PAMSys sensor for more than 12 hours a day. Over time, increases in the 95th percentile of variability in step duration were associated with higher disease severity as measured by the modified PSPRS-21 (r = 0.45, p = 0.021). Additionally, the median steps per walking bout was negatively correlated with disease severity (r = -0.38, p = 0.055), indicating that patients tend to take fewer steps on average as their symptoms worsened.

Conclusions The findings from this study demonstrate the feasibility of using wearable devices to monitor physical activity and falls in individuals with PSP. The observed correlations between sensor-derived metrics and disease severity provide valuable insights into the functional impairments associated with PSP. These results underscore the potential of digital health technologies in enhancing patient monitoring and guiding therapeutic interventions.

Authors/Disclosures
Jesse Wang PRESENTER	Mr. Wang has nothing to disclose.
Ram Kinker Mishra, PhD (Biosensics)	Dr. Mishra has received personal compensation for serving as an employee of BioSensics LLC.
AJ Hall (Johns Hopkins University)	AJ Hall has nothing to disclose.
Adonay Nunes (Biosensics)	Adonay Nunes has nothing to disclose.
Mansi Sharma (Massachusetts General Hospital)	Miss Sharma has nothing to disclose.
Claudia Waddell (Johns Hopkins University)	Claudia Waddell has nothing to disclose.
Vivian Zhao	Ms. Zhao has nothing to disclose.
Catherine Isroff, MD (Mass General Hospital)	Dr. Isroff has nothing to disclose.
Jose Casado (BioSensics LLC)	Jose Casado has received personal compensation for serving as an employee of Biosensics.
Hannah Jackson, Research Coordinator	Ms. Jackson has nothing to disclose.
Ashkan Vaziri, PhD (Biosensics LLC)	Dr. Vaziri has received personal compensation for serving as an employee of Biosensics.
Alexander Pantelyat, MD, FAAN (Johns Hopkins University School of Medicine)	Dr. Pantelyat has received personal compensation for serving as an employee of MedRhythms, Inc.. Dr. Pantelyat has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MedRhythms, Inc.. Dr. Pantelyat has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Kelly & Ignoffo Law Group. The institution of Dr. Pantelyat has received research support from NIH/NIA.
Anne Marie A. Wills, MD (MGH)	Dr. Wills has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Accordant, a CVS/Caremark company. Dr. Wills has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi/Genzyme. The institution of Dr. Wills has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ono Pharmaceuticals. The institution of Dr. Wills has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amylyx. Dr. Wills has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Parkinson's Foundation. The institution of Dr. Wills has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amylyx Pharmaceuticals. The institution of Dr. Wills has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ono Pharmaceuticals. The institution of Dr. Wills has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech. The institution of Dr. Wills has received research support from Parkinson's Foundation. The institution of Dr. Wills has received research support from Biogen. The institution of Dr. Wills has received research support from Roche/Genentech. The institution of Dr. Wills has received research support from BioSensics.

��ɫ��

��ɫ��